FabInhibitors: Addressing Unmet Medical Needs Caused by Bacterial Resistance
Germinated from assets acquired in 2003 from GSK, Affinium's antibacterial programs now include a broad base of intellectual property: issued and pending composition of matter patents on potent orally available small molecule inhibitors, genes, proteins, assays, crystal structures and combinations of FabInhibitors with known antibiotics. These assets represent a new class of antibiotics with a unique mechanism of action, targeting an unexploited pathway, bacterial fatty acid biosynthesis. With a lead compound entering the clinic, FabInhibitors represent a significant opportunity for multiple products and partnering opportunities.
Germinated from assets acquired in 2003 from GSK, Affinium's antibacterial programs now include a broad base of intellectual property: issued and pending composition of matter patents on potent orally available small molecule inhibitors, genes, proteins, assays, crystal structures and combinations of FabInhibitors with known antibiotics. These assets represent a new class of antibiotics with a unique mechanism of action, targeting an unexploited pathway, bacterial fatty acid biosynthesis. With a lead compound entering the clinic, FabInhibitors represent a significant opportunity for multiple products and partnering opportunities.
Duo an num quam fuisset sadipscing, elit animal doc endi enum num ut.